Cervical Cancer Diagnostic Test Market increasing consumer demand & will Grow, To reach $9.46 by 2021

Cervical Cancer Diagnostic Test Market increasing consumer demand & will Grow, To reach $9.46 by 2021

According to the report, the global cervical cancer diagnostic market accounted for USD 6.70 billion in 2015 and is expected to reach USD 9.46 by 2021, growing at a CAGR of around 5.9% between 2015 and 2021.

Cancer is defined as abnormal growth of cells with the potential to spread to other parts of the body. There are various types of cancer affecting different parts of the body. Cancer which develops in the cervix is called as cervical cancer. Two major types of cervical cancers diagnosed in women include adenocarcinoma and squamous cell carcinoma. Almost all types of cervical cancer are caused by human papiloma virus (HPV). Cervical cancer is the third most common cancer among women and the second most frequent cause of cancer-related death, accounting for almost 3,00,000 deaths annually. Diagnosis of cervical cancer is done by pap smear tests, colposcopy, HPV testing, endocervical curettage (ECC). Cervical cancer is a sexually transmitted disease that can be prevented by early detection and vaccination.

Request Free Sample Research Report @ http://atozresearch.com/cervical-cancer-diagnostic-test-market-pap-smear-tests-colposcopy-hpv-testing-endocervical-curettage-ecc-forecast-2015-2021/

Globally, cervical cancer diagnostic test market has been accelerated by increasing the percentage of HPV infected female population across the globe. According to the Center for Disease Control and Prevention (CDC), six million people in the U.S. acquire HPV each year.  At least 20 million already suffer from cervical cancer, and more than half of all sexually-active adults will be infected during their lifetime. Furthermore increasing the incidence of weakened immune system coupled with certain life history is also considered as a major governing factor which promotes the cause of cervical cancer in female and thus promotes the cervical cancer diagnostic market. Moreover many lifestyle-related factors, such as having multiple sex partners, smoking, obesity, unsafe sex and inherited HPV-positive patient, are estimated to drive the cervical diagnostics market. However, lack of education regarding the prevalence of cervical cancer and the unwillingness of the female population to undergo cervical cancer prognosis would hinder the growth of the market. In addition, HPV vaccination which makes people hesitant for conducting cervical cancer diagnostic test is also one of the restraining factors in a growth of cervical cancer diagnostic market.

Based on the test, the global market of cervical cancer diagnostic test is bifurcated into five types: Pap smear tests, colposcopy, HPV testing, endocervical curettage (ECC) and others (Cone Biopsy and Loop Electrosurgical Excision Procedure). The Pap smear tests segment accounted for the largest share of approximately more than 50% of the total cervical cancer diagnostic tests market in 2015. Factors attributed to the dominance of Pap smear tests are lower test prices and growing awareness about cancer diagnosis and benefits of early detection. Similarly, the HPV testing is forecast to grow at the fastest growth rate of approximately more than 9% from 2015 to 2021 of the cervical cancer diagnostic tests market. The rapid growth of the HPV testing segment is attributed due to the increasing incidence of HPV infections and risk of abnormal Pap test.

Based on end-user, the global market of cervical cancer diagnostics/test is bifurcated into three types: hospitals, laboratories, and others. The hospital’s segment was the leading segment in 2015. The segment is expected to continue its dominance during the forecast period.

Based on geographies, the global market of cervical cancer diagnostics/test is bifurcated into five regions: North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa. These segments are further bifurcated into the U.S., UK, Germany, France, China, Japan, India, and Brazil. North America accounted for the largest share of the global cervical cancer diagnostics/test market, followed by Europe. This growth is attributed due to rising awareness related to health care in this region. Moreover, cervical cancer diagnostics/test market has the huge opportunity in the emerging markets of Asia Pacific due to increasing standard of living, large patient base in this region. The Asia-Pacific market is projected to grow at the highest CAGR during the forecast period, due to the rising incidence of cervical cancer, increasing government support, and growing upper middle-class population and rise in disposable income levels in this region.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global cervical cancer diagnostic test market include Abbott Laboratories, Becton, Dickinson and Company, Femasys, Inc., Hologic, Inc., Guided Therapeutics, Inc., OncoHealth Corp., Quest Diagnostics, Inc., Roche Diagnostics, QIAGEN, and Zilico Ltd.